Cannabidiol as an add-on drug improves QoL in epilepsy I AES

L'accesso ai contenuti di questo sito è riservato agli operatori del settore sanitario italiano Registrati per accedere ai contenuti

Takeaway

  • Based upon preliminary analyses, cannabidiol (CBD) as an add-on drug for the treatment of pharmacoresistant epilepsy in a pediatric population does not appear to cause adverse effects involving cognition or adaptive function in patients who completed 1 year of treatment.

Why ...